Cargando…

Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors—An In Vitro Study

Factor (F) Xa inhibitors are safe and effective alternatives to warfarin. There are concerns about the lack of a reversal strategy in case of serious bleeds or need for emergency surgery in situations when the antidote andexanet alfa is not available. Factor concentrates are widely used, but there a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schultz, Nina Haagenrud, Fareed, Jawed, Holme, Pål Andre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Manuscript
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173996/ https://www.ncbi.nlm.nih.gov/pubmed/34060371 http://dx.doi.org/10.1177/10760296211021156

Ejemplares similares

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
por: Schultz, Nina Haagenrud, et al.
Publicado: (2017)

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
por: Schultz, Nina Haagenrud, et al.
Publicado: (2018)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
por: Stevens, Victoria M., et al.
Publicado: (2021)

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban‐treated patients in vitro
por: Schultz, Nina H., et al.
Publicado: (2017)

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021)

Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
por: Tao, Jing, et al.
Publicado: (2018)

Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019
por: Mohamed, Adham, et al.
Publicado: (2022)

Utility of Blood Cellular Indices in the Risk Stratification of Patients Presenting with Acute Pulmonary Embolism
por: Slajus, Brett, et al.
Publicado: (2021)

Revascularization of Peripheral Arteries in Patients with Intermittent Claudication Decreases Inflammatory Biomarkers
por: Poredoš, Pavel, et al.
Publicado: (2023)

Characterization of Aldosterone-producing Cell Cluster (APCC) at Single-cell Resolution
por: Iwahashi, Norifusa, et al.
Publicado: (2022)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

National Trends for Peripheral Artery Disease and End Stage Renal Disease From the National Inpatient Sample Database
por: De Stefano, Frank, et al.
Publicado: (2021)

The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients
por: Allen, Madeline, et al.
Publicado: (2023)

The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients
por: Jaradeh, Mark, et al.
Publicado: (2021)

Arterial-renal Syndrome in Patients with ESRD, a New Disease Paradigm
por: Goldstein, Jake, et al.
Publicado: (2022)

The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients
por: Kantarcioglu, Bulent, et al.
Publicado: (2022)

FRI166 Characterization of Aldosterone-producing Cell Cluster (APCC) At Single-cell Resolution
por: Iwahashi, Norifusa, et al.
Publicado: (2023)

Development and Implementation of an Online Global Pharmacovigilance Certificate Program During the COVID-19 Pandemic
por: Doan, Thao, et al.
Publicado: (2022)

Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism
por: O’Hara, Alexander, et al.
Publicado: (2023)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Collagen Remodeling and Fatty Acid Regulation Biomarkers in Understanding the Molecular Pathogenesis of Atrial Fibrillation
por: Odeh, Ameer, et al.
Publicado: (2022)

Potency Adjusted Blended Heparin of Bovine, Ovine, and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single-Sourced Porcine Heparin
por: Olson, Guy, et al.
Publicado: (2023)

Interrelationship Between Inflammatory Biomarkers and Collagen Remodeling Proteins in Atrial Fibrillation
por: Odeh, Ameer, et al.
Publicado: (2023)

Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)
por: Rajpurkar, Madhvi, et al.
Publicado: (2019)

Dysregulation of Biomarkers of Hemostatic Activation and Inflammatory Processes are Associated with Adverse Outcomes in Pulmonary Embolism
por: Darwish, Iman, et al.
Publicado: (2022)

Public Perceptions of Current COVID-19 Vaccinations. Results of a Pilot Survey
por: Kantarcioglu, Bulent, et al.
Publicado: (2021)

Regulation of Cortisol in Patients Undergoing Total Joint Arthoplasty
por: Khanna, Rajan, et al.
Publicado: (2021)

Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban by Andexanet Alfa as Measured by Whole Blood Thromboelastographic Analysis
por: Mehrotra, Siddharth, et al.
Publicado: (2022)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Genetic Variation in ADAMTS13 is Related to VWF Levels, Atrial Fibrillation and Cerebral Ischemic Events
por: Warlo, Ellen M. K., et al.
Publicado: (2022)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study
por: Singer, Adam J., et al.
Publicado: (2023)

Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version
por: Qneibi, Dalia, et al.
Publicado: (2020)

Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism
por: Kantarcioglu, Bulent, et al.
Publicado: (2022)

Cellular Indices and Outcome in Patients with Acute Venous Thromboembolism
por: Siddiqui, Fakiha, et al.
Publicado: (2022)

Application of Rotational Thromboelastometry in Patients with Acute Promyelocytic Leukemia
por: Sabljic, Nikica, et al.
Publicado: (2022)

Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale
por: Shaw, Joseph R., et al.
Publicado: (2023)

Fibrinolytic Status and Risk of Death After Acute Pulmonary Embolism
por: Brailovsky, Yevgeniy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r7hjid90su1t6oop2pej1j39pm